Targeted oncology therapies expand industry interest for Candel Therapeutics

Targeted oncology therapies expand industry interest for Candel Therapeutics
Candel Therapeutics shifts toward targeted care

Candel Therapeutics, Inc. is placing increased emphasis on targeted therapies within the oncology sector, as outlined by the company’s CEO, Paul Peter Tak, in a recent feature for PharmaTechFocus.

Tak discussed where viral immunotherapies fit into the evolving landscape, pointing to a growing integration of these innovative treatments within cancer care. The company continues to evaluate opportunities within immunotherapy and oncology, indicating a broader industry tilt toward precision medicine approaches.

Candel has previously outlined plans to present key phase 3 trial follow-up data for its CAN-2409 therapy in prostate cancer at AUA2026, according to a company statement. The company is also advancing viral immunotherapies across prostate, lung, and brain cancer programs, as detailed in its latest research updates. These efforts form part of Candel’s continuing focus on targeted oncology solutions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.